#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant fibrous histiocytoma Thrombocytopenia Retinal artery occlusion Langerhans' cell histiocytosis Gastrointestinal cancer metastatic Gastric cancer Hereditary ataxia Non-Hodgkin's lymphoma Niemann-Pick disease Myelofibrosis Brain injury Crigler-Najjar syndrome Angiosarcoma non-metastatic Pleomorphic liposarcoma Mantle cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia – Trials in Disease Rhabdomyosarcoma – Diagnostics Mucopolysaccharidosis – Diagnostics Advanced systemic mastocytosis – Basic Information Myxofibrosarcoma – Life with Disease Mucous membrane pemphigoid – Diagnostics SAPHO syndrome – Trials in Disease Lennox-Gastaut syndrome – Life with Disease Hairy cell leukaemia recurrent – Diagnostics Anaplastic thyroid cancer – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Omp66 Neridronate Sodium Bromhexine Hydrochloride Rhh646 Padeliporfin Protamine Sulfate Piritramide Metronidazole Pozelimab VINBLASTINE Metreleptin Vindesine Sulfate Metyrapone Hydrocortisone Ph. Eur. Hydralazine Hydrochloride Tramadol PAPAVERINE HYDROCHLORIDE Ifinatamab Deruxtecan Zinc Acetate Dihydrate Hypromellose More therapies…

    Learn about Your Condition

    Meningioma malignant Liposarcoma Head injury Transplant rejection Embolism Hyperphagia Pharyngeal cancer stage II Somatic symptom disorder Osteochondrodysplasia Diabetic foot Bacterial prostatitis Ewing's sarcoma Lymphoedema Eczema Triple negative breast cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

    Not recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Greece Hungary Poland Portugal +1

  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Finland France +9

  • Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Pembrolizumab, Vibostolimab, and Favezelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to BCG Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Favezelimab
    • Vibostolimab
    • Pembrolizumab
    Finland France Greece Italy The Netherlands Spain +1

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Systemic sclerosis pulmonary
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Vixarelimab
    Belgium France Germany Greece Hungary Italy +2

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Antiemetics And Antinauseants
    • Antipsychotics
    • Capecitabine
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Colestyramine
    • Teriflunomide
    • Frexalimab
    Austria Bulgaria Croatia Czechia Denmark France +10

  • Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

    Not recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Cenerimod
    Bulgaria France Greece Poland Romania

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma urethra
    • Transitional cell cancer of the renal pelvis and ureter
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Vinflunine
    • Docetaxel
    • Paclitaxel
    Belgium France Germany Greece Ireland Italy +2
Previous Page
1 … 18 19 20 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!